



(51) International Patent Classification:

A61K 31/122 (2006.01) A61K 31/713 (2006.01)
A61K 31/4745 (2006.01) A61K 39/00 (2006.01)
A61K 31/506 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/020307

(22) International Filing Date:

15 March 2024 (15.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,995 17 March 2023 (17.03.2023) US
63/581,184 07 September 2023 (07.09.2023) US

(71) Applicant: MDX MANAGEMENT LLC [US/US]; 9046
La Jolla Shores Lane, La Jolla, California 92037 (US).

(72) Inventors: LIU, Yuan; 1150 Gavinwood Place, Decatur,
Georgia 30033 (US). SHI, Lei; 702 Avondale Hill Drive,
Decatur, Georgia 30032 (US). BIAN, Zhen; 76 Staley Drive,
Tucker, Georgia 30084 (US). STYLLI, Harry; 9046 La
Jolla Shores Lane, La Jolla, California 92037 (US).

(74) Agent: YOU, Yuying et al.; Morrison & Foerster LLP, 755
Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES




FIG. 35B

(57) Abstract: The present application provides a method of treating a cancer in an individual that involves administering to the individual a myeloid cell activating agent or therapy (such as a TLR agonist or a STING agonist) and a TNF α inhibitor. In some cases, the method further involves administering a SHP-1 inhibitor and/or tyrosine kinase inhibitor to the individual, optionally further administering a lymphocyte activating agent such as a cytokine (such as IL-2) and/or an immune checkpoint inhibitor (such as anti-PD-1).

[Continued on next page]

Published:

— with international search report (Art. 21(3))